A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers

Paul K. Paik1,2, Ronglai Shen1,3, Michael F. Berger4,5, David Ferry6, Jean-Charles Soria7, Alastair Mathewson8, Claire Rooney8, Neil R. Smith8, Marie Cullberg8, Elaine Kilgour8, Donal Landers8, Paul Frewer8, Nigel Brooks8, and Fabrice André7

Abstract

Purpose: Squamous cell lung cancers (SQCLCs) account for 25% of all NSCLCs, yet the prognosis of these patients is poor and treatment options are limited. Amplified FGFR1 is one of the most common oncogenic events in SQCLCs, occurring in approximately 20% of cases. AZD4547 is a potent and selective FGFR1 inhibitor with antitumor activity in FGFR1-amplified SQCLC cell lines and patient-derived xenografts.

Experimental Design: On the basis of these data, we performed a phase I study of AZD4547 in patients with previously treated stage IV FGFR1-amplified SQCLCs (NCT00979134). FGFR1 amplification (FGFR1-CEP8 ≥ 2) was determined by FISH. The primary endpoint was safety/tolerability. Secondary endpoints included antitumor activity, pharmacokinetics, pharmacodynamics, and molecular analyses.

Results: Fifteen FGFR1-amplified patients were treated. The most common related adverse events (AE) were gastrointestinal and dermatologic. Grade ≥3-related AEs occurred in 3 patients (23%). Thirteen patients were evaluable for radiographic response assessment. The overall response rate was 8% (1 PR). Two of 15 patients (13.3%) were progression-free at 12 weeks, and the median overall survival was 4.9 months. Molecular tests, including next-generation sequencing, gene expression analysis, and FGFR1 immunohistochemistry, showed poor correlation between gene amplification and expression, potential genomic modifiers of efficacy, and heterogeneity in 8p11 amplicon.

Conclusions: AZD4547 was tolerable at a dosage of 80 mg oral twice a day, with modest antitumor activity. Detailed molecular studies show that these tumors are heterogeneous, with a range of mutational covariates and stark differences in gene expression of the 8p11 amplicon that likely explain the modest efficacy of FGFR inhibition in this disease.

Cancer Therapy: Clinical

Introduction

Despite the recent FDA-approval of a number of new treatment options for patients with squamous cell lung cancers (SQCLCs), efforts at targeting genetic aberrations in these patients have been largely unsuccessful. There are a number of reasons for this, including a paucity of experimental models that accurately recapitulate patients’ tumors and a general focus on actionable driver events that occur in adenocarcinomas but are absent in SQCLCs. From the standpoint of personalized therapy, management has been, as a result, impersonal, a reflection of our poor understanding of the biology of this disease. Recently, however, The Cancer Genome Atlas’ comprehensive molecular analysis of 178 early-stage SQCLC tumors (1) along with parallel work by other investigators identified a number of potentially actionable oncogenic events in this disease, including mutations in the Discoidin Domain Receptor 2 gene (DDDR2; ref. 2) and amplification of the Fibroblast Growth Factor Receptor 1 gene (FGFR1; ref. 3). The latter has been a particularly promising target given its relatively high event frequency (approximately 20% of tumors in some series) and encouraging preclinical modeling, which confirmed its oncogenic potential and sensitivity to pharmacologic inhibition (3, 4).

AZD4547 is a potent and selective inhibitor of FGFR 1, 2, and 3. Cellular enzyme inhibition assays demonstrate high potency against FGFRs 1 to 3 (IC50 = 13 nmol/L for FGFR1, 2 nmol/L for FGFR2, and 40 mol/L for FGFR3) with good selectivity: the insulin-like growth factor 1 receptor (IGF1R, IC50 = 629 nmol/L) and kinase insert domain receptor (KDR, IC50 = 285 nmol/L) are the only other kinases with sub-micromolar IC50s. An antecedent to AZD4547 (4).

AZD4547 was tolerable at a dosage of 80 mg oral twice a day, with modest antitumor activity. Detailed molecular studies show that these tumors are heterogeneous, with a range of mutational covariates and stark differences in gene expression of the 8p11 amplicon that likely explain the modest efficacy of FGFR inhibition in this disease.

Cancer Research

Note: Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Corresponding Author: Paul K. Paik, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065. Phone: 646-888-4202; Fax: 646-888-4263. E-mail: paikp@mskcc.org

doi: 10.1158/1078-0432.CCR-17-0645
©2017 American Association for Cancer Research.
Translational Relevance

Initial attempts at identifying targeted therapies for patients with squamous cell lung cancers (SQCLC) have largely failed, despite relatively detailed knowledge of the somatic events that occur in these cancers. The reasons for this are not clear. Current hypotheses center around the functional validity of the current panel of biomarkers and the role of genomic complexity as it relates to bypass pathways. None of this has been shown to be clinically relevant to date. We present clinical and molecular data that show that targeted therapy development for FGFR1-amplified SQCLCs will need to adjust for the molecular complexity of these tumors in a more comprehensive fashion for existing and future trials, with implications for other targeted efforts in this disease.

Materials and Methods

Patient eligibility

All patients had a histologic diagnosis of stage IV SQCLC, confirmation of FGFR1 amplification by FISH, WHO performance status of 0 to 1, and normal renal, hepatic, and hematologic function. Patients needed to have had disease progression following first-line platinum-based chemotherapy with measurable disease as per RECIST 1.1. Key exclusion criteria included a history or evidence on screening of specific ophthalmologic conditions including retinal pigmented epithelium detachment (RPED), dry or wet age-related macular degeneration, retinal vein occlusion (RVO), retinal degenerative diseases, or any other chorioretinal defect.

Study design and treatment

This was an international phase Ib study of AZD4547 monotherapy conducted at 29 centers in 7 countries (United Kingdom, United States, Spain, Germany, the Netherlands, France, and Italy). The study protocol was approved by the Institutional Review Boards (IRB) at each institution and in accordance with the Declaration of Helsinki. The primary endpoints of this study were to characterize the safety, tolerability, and preliminary antitumor activity of AZD4547 in the recommended expansion dose in this population of patients. A sample size of 12 evaluable patients was considered adequate to detect a difference in preliminary antitumor activity of AZD4547 at the recommended expansion dose in this molecularly defined cohort. Patients received treatment with AZD4547 at a dose of 80 mg oral twice daily continuously on an every 21-day cycle. Toxicity was graded according to the NCI Common Toxicity Criteria version 4.0. Ophthalmologic assessments (including ophthalmologic CT) were required at baseline, monthly for the first 3 months, then every 8 weeks thereafter. Tumor size was assessed by CT imaging of all known sites of disease every 2 cycles (6 weeks). Response and determination of progression were made using RECIST 1.1 by local investigators. Response confirmation was made with a follow-up scan at least 4 weeks after the initial assessment. Progression-free survival was assessed and reported at 12 weeks. Median overall survival (OS) was calculated using the Kaplan–Meier method.

Blood for AZD4547 pharmacokinetic analysis was obtained on day 1 of cycles 2 and 3 at the following time-points: predose, 0.5 to 2 hours postdose, 5 to 6 hours postdose, and 8 to 12 hours postdose. Plasma drug concentration was analyzed by PRA International. Blood for FGF2 and FGF23 ligand assessment was obtained at screening pre-dose on days 1, 8, and 15 of cycle 1, and predose on day 1 of every cycle thereafter.

Determination of FGFR1 amplification

For the purposes of trial eligibility, FGFR1 amplification by FISH was determined through central testing using a noncommercial DAKO Kit (N = 13, Quintiles) and by local testing using a ZytoVision SPEC FGF1/CEN 8 probeset (N = 2, images centrally reviewed for confirmation). Amplification was defined as a ratio of 8p signals ≥2 relative to the centromere. Amplification was further stratified as "low" (ratio 2.0–2.6) and "high" (ratio ≥ 2.6) for the purposes of response assessment.

Next-generation sequencing

Genomic alterations in key cancer-associated genes were profiled using two platforms. Ten samples were analyzed using an exon capture by hybridization followed by next-generation sequencing assay termed MSK-IMPACT (Integrated Mutation Profiling of Actionable Cancer Targets), which encompasses all protein-coding exons and select introns of 341 cancer genes (5, 6). Genes were selected to include commonly implicated oncogenes, tumor suppressor genes, and components of pathways deemed actionable by current-targeted therapies (Supplementary File S1). All somatic alterations were called in reference to matched germline DNA. One additional sample was analyzed through FoundationONE. Calls for copy number gain and amplification utilized cut-off ratios of between 1.6 and 2 and ≥2, respectively, normalized against the average ploidy of the tumor.

RNA extraction and gene expression by NanoString analysis

Prior to processing tumor for RNA extraction, each sample was reviewed by an internal certified pathologist to confirm disease diagnosis and verify tumor content. A minimum of one 5-μm section per patient was used; however, where tumor size or content was small two sections were used. RNA was extracted from macrodissected tissue using the Allprep DNA/RNA Kit (Qiagen) according to the manufacturer’s instructions. RNA quantity was assessed by Qubit (Thermo Fisher Scientific).

Barcoded probes to measure gene expression were manufactured by NanoString Technologies (Supplementary File S2). The nCounter assay also included six positive controls and eight negative controls. nCounter analysis was performed according to the manufacturer’s instructions. Data were collected using the nCounter digital analyzer. nCounter data were normalized through an internally developed Pipeline Pilot Tool [NAPPA, publicly available on the Comprehensive R Archive Network].
patients were treated as part of the dose-escalation cohort at the dose of AZD4547 across the phase I cohorts. Thirteen of these

**Clinical characteristics**

Table 1.

**Results**

**FGFR1 IHC**

FFPE tissue sections (5 μm) were placed onto glass slides, dewaxed, and rehydrated. All incubations were performed at room temperature and TBS containing 0.05% Tween (TBST) used for washes. Antigen retrieval was performed in pH 6 retrieval buffer (S1659, Dako) at 110°C for 5 minutes in a RHS-1 microwave vacuum processor (Milestone), then peroxidase activity (3% hydrogen peroxide for 10 minutes), endogenous biotin (Vector, SP-2002), and nonspecific binding sites (Dako, X0909) blocked. 1:50 FGFR-1 antibody (Epitomics 2144-1), in antibody diluent (Dako, S0809), was applied to sections for 1 hour. The Vectastain Elite ABC Kit (Vector, PK-6101) was then added as instructed. Sections were washed and developed in diaminobenzidine for 10 minutes (Dako, K3466) then counterstained with Carazzi’s hematoxylin.

Controls included the FFPE KG1a [FGFR-1 expressing (FGFR2/3 negative)] xenograft tumor as a positive control and the FFPE KMS11 [FGFR-3 expressing (FGFR2/3 negative)] xenograft tumor as a negative control. Percent tumor content from each patient sample is shown in Supplementary File S3.

**Table 2. Most frequent grade ≥2 adverse events**

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>N (% frequency)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Constipation</td>
<td>8 (33.3)</td>
</tr>
<tr>
<td>Dry mouth</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Fatigue</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Diarrhea</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>5 (33.3)</td>
</tr>
<tr>
<td>Decreased appetite</td>
<td>4 (26.7)</td>
</tr>
<tr>
<td>Vomiting</td>
<td>4 (26.7)</td>
</tr>
<tr>
<td>Dry skin</td>
<td>4 (26.7)</td>
</tr>
<tr>
<td>Breath sounds abnormal</td>
<td>4 (26.7)</td>
</tr>
<tr>
<td>Dry eye</td>
<td>3 (20.0)</td>
</tr>
<tr>
<td>Stomatitis</td>
<td>3 (20.0)</td>
</tr>
<tr>
<td>Epistaxis</td>
<td>3 (20.0)</td>
</tr>
<tr>
<td>Hyperphosphatemia</td>
<td>3 (20.0)</td>
</tr>
<tr>
<td>Nausea</td>
<td>2 (13.3)</td>
</tr>
<tr>
<td>Anemia</td>
<td>2 (13.3)</td>
</tr>
<tr>
<td>Onychomadesis</td>
<td>2 (13.3)</td>
</tr>
</tbody>
</table>

expansion cohort and are excluded from this analysis as non-amplified. The clinical characteristics of the 15 FGFR1-amplified patients treated are shown in Table 1. Prior treatments received by each patient, along with responses where available, are shown in Supplementary File S4.

The most frequent grade ≥ 2 adverse events (AE) are shown in Table 2. Toxicities generally affected the gastrointestinal tract and mucosal/cutaneous surfaces. Six patients (40%) experienced a grade ≥ 3 AE. Three (23%) patients in the SQCLC expansion cohort experienced a serious adverse event (SAE) related to study drug (Table 3). Two patients in the preceding dose-escalation cohort experienced central serous retinopathy and dehydration (both related, grade 3) and grade 5 deterioration (unrelated) as SAEs. Three patients in the SQCLC expansion (23%) discontinued therapy due to side effects from study drug, which included asthenia, bilateral central subfoveal edema, and general deterioration. There were no treatment-related deaths. Two patients came off study prior to undergoing their first CT scan, one for toxicity and the other from death due to disease.

Of the 13 patients who underwent a follow-up CT scan, one achieved a confirmed partial response (PR, 8%), four patients had stable disease (SD, 31%) as a best response and the remaining eight patients had progression of disease (PD, 61%; Fig. 1). Two of fifteen (13.3%) patients were progression free at 12 weeks. Median OS was 4.9 months.

FGFR1 amplification, protein, and mRNA expression uncover heterogeneity in the 8p11 amplicon

To explore whether molecular covariates might play a role in determining response to AZD4547, we performed targeted exon sequencing, IHC, and gene expression analysis on all available archived pretreatment tumors. Eleven of 15 patients had adequate material for next-generation sequencing. A full list of the somatic variants and copy number alterations can be found in Supplementary File S5, with a subset of results presented in Fig. 1. Of the 11 patients tested (10 of whom were evaluable for CT response as shown in Fig. 1), four (36%) had evidence of FGFR1 amplification (ratio ≥2, normalized to average tumor ploidy) and five (45%) had evidence of gain (ratio = 1.6–2.0) by sequencing. Two patients had no evidence of amplification by sequencing (18%).

IHC for FGFR1 was performed on samples from eight patients (Fig. 1). There was no correlation between FGFR1 protein expression and degree of gene amplification either by FISH or by
Next-generation sequencing identifies molecular covariates as potential response modifiers

Because SQCLCs are often marked by changes within or across multiple signaling pathways, we screened for somatic co-alterations in other putative oncogenic drivers and tumor suppressors, including those within the commonly altered PI3K and cell-cycle pathways. These are listed in Fig. 1. Most tumors had either amplification of a cyclin or cyclin-dependent kinase or an inactivating CDKN2A alteration (N = 8/11, 72%). Most did not have co-alteration in an upstream PI3K pathway member (N = 4/11, 36%). Neither PI3K pathway alterations nor G1–S checkpoint alterations seemed to correlate with response in a predictable fashion, with the one confirmed partial responder's tumor harboring PIK3CA amplification, CCND1/3 amplification, and CDKN2A loss.

We did identify other somatic alterations, however, with the potential to modify response. These included FGFR3 S249C, FGFR1 D131N, FGFR1 D93Y and H841Y, and NOTCH1 E1929* mutations as potential sensitizers and a KEAP1 R260* mutation and MYC amplification as potential resistance factors.

AZD4547 pharmacokinetics

The plasma concentration of AZD4547 was assessed on day 1 of cycles 2 and 3 pre-dose and during prespecified time windows post-dose. There was variability in the pharmacokinetics between patients, in part because of dose reductions from 80 to 40 mg twice a day in one patient, making specific correlative assessments difficult (Supplementary File S6). Overall, across the histologic expansion arms of the study (Part C), the predose geometric mean concentrations were similar at cycle 2 and 3, ranging from 92.5 to 182.2 ng/mL and 56.8 to 170.3 ng/mL, respectively, suggesting stability in the pharmacokinetics of AZD4547 over time. There was no clear correlation between C2D1 or C3D1 pharmacokinetics data and response, either by RECIST or unidimensional shrinkage (Supplementary Fig. S2).

Serum phosphate pharmacodynamics and response

FGF23 is a potent phosphatonin that causes renal phosphate excretion upon binding to FGFR1 and its co-receptor klotho. Serum phosphate is thus a pharmacodynamic biomarker of FGFR1 inhibition in renal cells. As shown in Fig. 3A, there was a modest but significant increase in average serum phosphate of about 0.4 mmol/L, or 1 mg/dL, from patients treated with AZD4547 at cycle 2 day 1 (P < 0.001). We analyzed the relationship between best percent change in tumor size and increase in serum phosphate as stratified by degree of FGFR1 amplification (Fig. 3B). Patients who were treated with the phosphate binder renagel were excluded from this analysis. There was a significant association between the best change in tumor size and increase in serum phosphate at cycle 2 day 1 in patients whose tumors had a high degree of FGFR1 amplification (P < 0.001). FGF2 and FGF23 ligand dynamics were also studied but showed a substantial amount of intrapatient variability without apparent correlation with response or pharmacokinetics (data not shown).

Discussion

This is, to our knowledge, the first prospective study of FGFR1 inhibition in patients with FGFR1-amplified stage IV SQCLCs to report relatively comprehensive data on the molecular landscape of these tumors, with an eye towards elucidating the relationship between gene, RNA, and protein expression. Although preclinical studies provided a strong rationale for kinase inhibition in this setting, the clinical data to date show only modest efficacy in this study as well as studies of the pan-FGFR inhibitor BG19398 and the multi-kinase inhibitor dovitinib (7, 8). Correlative studies performed by us suggest two possible explanations for this.

First, although all patient tumors exhibited FGFR1 amplification by FISH, only a subset was found to have amplification of a cyclin or cyclin-dependent kinase or an inactivating CDKN2A alteration (N = 8/11, 72%). Most did not have co-alteration in an upstream PI3K pathway member (N = 4/11, 36%). Neither PI3K pathway alterations nor G1–S checkpoint alterations seemed to correlate with response in a predictable fashion, with the one confirmed partial responder's tumor harboring PIK3CA amplification, CCND1/3 amplification, and CDKN2A loss.

We did identify other somatic alterations, however, with the potential to modify response. These included FGFR3 S249C, FGFR1 D131N, FGFR1 D93Y and H841Y, and NOTCH1 E1929* mutations as potential sensitizers and a KEAP1 R260* mutation and MYC amplification as potential resistance factors.

Table 3. Serious adverse events

<table>
<thead>
<tr>
<th>Adverse event</th>
<th>Grade</th>
<th>Related to AZD4547</th>
</tr>
</thead>
<tbody>
<tr>
<td>Central serous retinopathy</td>
<td>3</td>
<td>Yes</td>
</tr>
<tr>
<td>Dehydration</td>
<td>3</td>
<td>Yes</td>
</tr>
<tr>
<td>Deterioration</td>
<td>5</td>
<td>No</td>
</tr>
<tr>
<td>Anoxia</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>Asthenia</td>
<td>2</td>
<td>Yes</td>
</tr>
<tr>
<td>Dyspnea/hypoxia</td>
<td>2</td>
<td>No</td>
</tr>
<tr>
<td>Deterioration</td>
<td>3</td>
<td>No</td>
</tr>
<tr>
<td>Dyspnea</td>
<td>2</td>
<td>Yes</td>
</tr>
<tr>
<td>Hyponatremia</td>
<td>4</td>
<td>No</td>
</tr>
</tbody>
</table>

The maximum H-score was 160 (range 0–160), with four patient tumors (50%) showing no evidence of protein expression (H-score = 0, patients 2, 4, 15, and 7). Three patients had multiple tumor areas available for IHC assessment. IHC of these areas showed heterogeneity in FGFR1 protein expression, with one patient's tumor samples showing H-scores of 2, 10, and 145 and another's showing scores of 0, 20, and 80. We did find evidence of FGFR1 heterogeneity by FISH as well in samples from Patient 4 and in a patient untreated with drug but whose tumor underwent screening (Supplementary Figs. S1A and S1B).

We assessed for FGFR1 mRNA expression as part of a broader panel of genes located in the 8p11 amplicon. Eight patients had material left for this analysis, which was also performed on FGFR1-amplified (positive controls) and nonamplified (negative controls) lung cancer cell lines. As shown in Fig. 2, the pattern of gene expression in our patients’ tumors was strikingly different from those seen in the FGFR1-amplified positive controls (DMS114, H520, H1703). Although nearly all 8p11 genes were concordantly and highly expressed in the FGFR1-amplified cell lines, gene expression in the patient tumor samples was variable and lower. Some exhibited higher expression in genes located closer to the centromere (patients 5 and 8) whereas others exhibited uniformly low expression of all 8p11 genes (patients 3, 4A, 2A). Still others showed a fragmented expression pattern (patient 4C and 11). With regard to FGFR1 in particular, gene expression was relatively low in most patients’ tumors. We did identify heterogeneity in FGFR1 mRNA expression in one patient who had two sites of disease available for testing, commensurate with the heterogeneous protein expression detected by IHC (patients 2A and B). Overall, protein expression did match gene expression where material was available for both assays. Importantly, however, neither occurred at high level in any tumor sample. MYC mRNA expression was also assessed in eight patients, and although present in all tested cases, was not overexpressed relative to FGFR1 in any case (data not shown).
level analysis of the 8p11 amplicon. Our gene expression data does, however, provide strong evidence of heterogeneity in the 8p11 amplicon, as the patterns of gene expression in our patients’ tumors were strikingly different from those seen in the FGFR1-amplified cell lines. That these cell lines are exquisitely sensitive to FGFR1 pharmacologic inhibition suggests that these differences are biologically meaningful.

In line with the gene expression results, FGFR1 protein expression poorly correlated with gene amplification, with five of eight tumor samples showing no or very low protein expression, including the one from our confirmed partial responder (Patient 7, although this may reflect a false negative result in the absence of confirmatory gene expression data). As FGFR1 amplification correlates poorly with gene and protein expression, we question the functional relevance of these biomarkers assessed in isolation for most patients, a concern raised by investigators in other studies (10). It is worth noting that some of this may be due to intra- and intertumoral heterogeneity as suggested by variability in FGFR1 protein expression in different tumor specimens tested from the same patient and from other work published by us previously (11). It is also worth noting that none of our patients had tumors that were “triple positive” (high FGFR1 gene amplification, gene expression, and protein expression), and so we were unable to assess the predictive impact of a tumor with consistent high-level expression of FGFR1, which might define a smaller, targetable subset of FGFR1-amplified SQCLCs. Indeed, the four SQCLC PDXs generated by Zhang and colleagues that showed tumor regression or sustained growth inhibition in response to AZD4547 also showed high levels of FGFR1 protein expression by IHC and western blot relative to the negative control (4). The one FGFR1-amplified PDX that did not (L133) respond to drug exhibited low levels of FGFR1 protein expression by IHC and Western blot analysis. And although Camidge and colleagues have detailed the predictive value of very high levels of MET amplification (ratio ≥ 5) in NSCLC (12), the lack of responses in our study and poor correlation with protein/RNA expression again limits our ability to comment on patients whose tumors bear very high degrees of FGFR1 amplification.

Second, other factors may be at play in dictating sensitivity to FGFR1 inhibition in the patients who demonstrated tumor response in our study. Examples include Patient 15’s tumor (G1−S checkpoint), which harbored an FGFR3 S249C mutation, a common activating mutation in bladder cancer that causes ligand-independent dimerization and phosphorylation of the receptor with...
known susceptibility to FGFR inhibition (13, 14). Patient 6’s tumor (−20%) contained two somatic missense mutations in FGFR1, including a mutation (D93Y) in the first immunoglobulin (Ig)-like domain (D1). Although the functional relevance of this mutation is not known, crystallographic work suggests that it might alter the ability of the D2 Ig-like domain to bind to heparin, which is required for ligand-independent activation of the receptor (15).

Patient 7 was the only patient to develop a PR to AZD4547. Interestingly, sequencing uncovered a NOTCH1 E1929 nonsense mutation, which causes deletion of the key C-terminal ankyrin repeats in Notch1. Notch1 is a type 1 transmembrane receptor that has important roles in determining cell differentiation, proliferation, and survival. The C-terminal notch intracellular domain (NICD) consists of seven highly conserved ankyrin repeats. Activation of Notch1 causes cleavage of the NICD, which localizes to

---

**Figure 2.**
Heatmap for mRNA expression of select genes located on the 8p11 amplicon, arranged from centromere (left) to telomere (right). Red coloration denotes high expression and green denotes low expression for a given tumor sample. Gray denotes no detection of gene expression. H-score for FGFR1 protein expression is indicated on the right where available. DMS114, H520, and H703 NSCLC cell lines were included as positive controls (FGFR1 amplified); H596 and HCC15 NSCLC cell lines were included as negative controls (FGFR1 nonamplified).

---

**Figure 3.**
A, Plot of serum phosphate concentration for each patient at cycle 1 day 1 and cycle 2 day 1. Thicker black line indicates mean phosphate concentration. B, Plot of serum phosphate concentration at cycle 2 day 1 against best % change in tumor size parsed by FISH low- and high-amplification status. There was a significant association between higher serum phosphate concentration and best change in % tumor size in the high-amplification group (P < 0.001).
the nucleus and acts as a transcriptional activator (16). Deletion of the NICD creates a dominant negative form of the protein (17). Small and colleagues (16) previously showed that Notch1 repression potentiates the oncogenicity of wild-type FGFR1. NIH 3T3 cells stably transfected with a dominant negative form of Notch1 (lacking the NICD) exhibited anchorage-independent growth and robust colony formation upon FGFR1 simulation that was not seen in Notch1-active conditions. This effect was abrogated by the addition of the FGFR1 inhibitor PD166866. Notch1 repression was also associated with the induction of FGFI, 3, 4, and 5 mRNA and protein suggesting that autocrine production of FGFR1-activating ligands may determine the degree to which FGFR1 is an oncogenic driver. This is in keeping with data from Malchers and colleagues (9), who identified autocrine production of FGFR2 as a potential mediator of response to FGFR1 inhibition in an FGFR1-amplified SQCLC model. Although MYC expression was also assessed, Patients 6 and 7 (20%, 35% response) had insufficient tumor material for testing, preventing us from ruling-out lack of MYC expression as a potential sensitizer (9).

Finally, paired pretreatment/posttreatment tumor biopsies were not obtained in this study, precluding a direct assessment of FGFR1 pathway inhibition. That said, the observed elevation in serum phosphate was a well-characterized on-target effect of the drug attributable to inhibition of FGFR2 signaling through FGFR1 in the kidney. We note that the antecedent phase I dose finding study showed that higher doses of AZD4547 induced greater elevations in serum phosphate. Higher drug doses might, therefore, yield an improvement in efficacy, though with increased and likely unacceptable toxicity.

In conclusion, AZD4547 appears to have modest efficacy in patients with previously treated stage IV FGFR1-amplified SQCLC. Gene amplification does not correlate well with gene and protein expression. Other common genomic modifiers, specifically G1–S checkpoint aberrations and PI3K pathway alterations, do not appear to mediate sensitivity to FGFR1 inhibition. Gene expression analysis of the 8p11 amplon demonstrates divergent patterns of expression in our patients’ tumors compared to FGFR1-amplified cell lines, the latter of which are known to be exquisitely sensitive to drug inhibition. Future studies should move away from FGFR1 gene amplification and expression as predictive biomarkers and focus instead on discrete genomic events involving the FGFR1 (missense mutations, translocations) or more detailed assessments of 8p11 amplification or pathway activation as predictors of response. Until this occurs, combinatorial therapy coupling FGFR1 inhibition with, for example, PI3K or CDK4/6 inhibition is also unlikely to work. This is of particular clinical relevance as large-scale targeted therapy efforts in this disease, such as SWOG’s S1400 (LUNG-MAP) protocol, move beyond their first-generation monotherapy efforts to consider other therapeutic strategies.

Disclosure of Potential Conflicts of Interest
J.-C. Soria is a consultant/advisory board member for AstraZeneca. C. Rooney and E. Kilgour hold ownership interest (including patents) in AstraZeneca. D. Landers is an employee of Cancer Research UK. F. André reports receiving commercial research grants from AstraZeneca. No potential conflicts of interest were disclosed by the other authors.

Authors’ Contributions
Conception and design: P.K. Paik, C. Rooney, E. Kilgour, P. Fewer, N. Brooks
Development of methodology: P.K. Paik, A. Mathewson, C. Rooney, N. Brooks
Acquisition of data (provided animals, acquired and managed patients, provided facilities, etc.): P.K. Paik, D. Ferry, J.-C. Soria, A. Mathewson, N.R. Smith, E. Kilgour, F. André
Writing, review, and/or revision of the manuscript: P.K. Paik, D. Ferry, J.-C. Soria, A. Mathewson, C. Rooney, N.R. Smith, M. Cullberg, E. Kilgour, D. Landers, P. Fewer, F. André
Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): P.K. Paik, A. Mathewson, N.R. Smith
Study supervision: P.K. Paik, A. Mathewson, N.R. Smith

Grant Support
This work was supported by the grant P30 CA086748.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received March 6, 2017; revised May 1, 2017; accepted June 7, 2017; published OnlineFirst June 14, 2017.

References


Clinical Cancer Research

A Phase Ib Open-Label Multicenter Study of AZD4547 in Patients with Advanced Squamous Cell Lung Cancers


Updated version
Access the most recent version of this article at:
doi:10.1158/1078-0432.CCR-17-0645

Supplementary Material
Access the most recent supplemental material at:
http://clincancerres.aacrjournals.org/content/suppl/2017/06/14/1078-0432.CCR-17-0645.DC1

Cited articles
This article cites 17 articles, 8 of which you can access for free at:
http://clincancerres.aacrjournals.org/content/23/18/5366.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.